Recent

% | $
Quotes you view appear here for quick access.

BioCryst Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • joe_dirts_brother joe_dirts_brother Nov 8, 2012 10:21 AM Flag

    Next week meeting - positive news

    And the cheap glassware and office furniture PARKING LOT SALE- maybe ole WHACKO-JAC can get his mom to drive him down there and get him a desk for the basement so he can start SCHOOL, and get an actual education. I'm WHACKO-JAC, "I play a CEO, an investment banker, an investment club adviser and bio tech analyst in my fantasies- while I have no GED or even high school diploma and live out of my single parent, mother's basement". I play video games and masturbate profusely while not playing imaginary Star Trek convention roles such as Star Ship Captain or CEO of companies. I am JACK HEMMERBOY and I approve this message.

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • That news will be related to:
      Presidio is a clinical stage pharmaceutical company that is developing small-molecule antiviral therapeutics for the treatment of chronic hepatitis C virus infection. Its lead HCV candidate, PPI-668, is an oral, once-daily, pan-genotypic HCV inhibitor targeting the viral NS5A protein, and is ready to enter Phase 2 clinical development. In a Phase 1b trial in patients with HCV genotype 1a and 1b, PPI-668 dosed once-daily at 40 mg to 240 mg produced mean maximal viral RNA load reductions of 3.5-3.7 log10 during three days of treatment at optimal dose levels. Presidio is also advancing PPI-383, a pan-genotypic, non-nucleoside inhibitor of the viral NS5B polymerase as a second, complementary HCV antiviral candidate. PPI-383 is currently undergoing IND-enabling studies to support initiation of clinical studies alone and in combination with PPI-668 during 2013.

      Sentiment: Strong Buy

 
BCRX
9.780.00(0.00%)Apr 17 4:00 PMEDT